|
1
|
Brahmer J, Reckamp KL, Baas P, Crino L,
Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550.
2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols
MC, et al: Atezolizumab versus docetaxel in patients with
previously treated non-small-cell lung cancer (OAK): A phase 3,
open-label, multicentre randomised controlled trial. Lancet.
389:255–265. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Gandhi L, Rodriguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic
non-small-cell lung cancer. N Engl J Med. 378:2078–2092.
2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Gainor JF, Shaw AT, Sequist LV, Fu X,
Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR, et
al: EGFR mutations and ALK rearrangements are associated with low
response rates to PD-1 pathway blockade in non-small cell lung
cancer: A retrospective analysis. Clin Cancer Res. 22:4585–4593.
2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Haratani K, Hayashi H, Tanaka T, Kaneda H,
Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, et
al: Tumor immune microenvironment and nivolumab efficacy in EGFR
mutation-positive non-small-cell lung cancer based on T790M status
after disease progression during EGFR-TKI treatment. Ann Oncol.
28:1532–1539. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Inomata M, Tanaka H, Tokui K, Taka C,
Okazawa S, Kambara K, Imanishi S, Yamada T, Miwa T, Hayashi R, et
al: Clinical course after initiation of nivolumab therapy in
patients with egfr-mutated non-small cell lung cancer with or
without Pd-L1 expression. Oncology Therapy. 5:181–185. 2017.
|
|
9
|
Hastings K, Yu HA, Wei W, Sanchez-Vega F,
DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, et al:
EGFR mutation subtypes and response to immune checkpoint blockade
treatment in non-small-cell lung cancer. Ann Oncol. 30:1311–1320.
2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sato M, Watanabe S, Tanaka H, Nozaki K,
Arita M, Takahashi M, Shoji S, Ichikawa K, Kondo R, Aoki N, et al:
Retrospective analysis of antitumor effects and biomarkers for
nivolumab in NSCLC patients with EGFR mutations. PLoS One.
14(e0215292)2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Masuda K, Horinouchi H, Tanaka M,
Higashiyama R, Shinno Y, Sato J, Matsumoto Y, Okuma Y, Yoshida T,
Goto Y, et al: Efficacy of anti-PD-1 antibodies in NSCLC patients
with an EGFR mutation and high PD-L1 expression. J Cancer Res Clin
Oncol. 147:245–251. 2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Isomoto K, Haratani K, Hayashi H, Shimizu
S, Tomida S, Niwa T, Yokoyama T, Fukuda Y, Chiba Y, Kato R, et al:
Impact of EGFR-TKI treatment on the tumor immune microenvironment
in EGFR mutation-positive non-small cell lung cancer. Clin Cancer
Res. 26:2037–2046. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Taniguchi Y, Tamiya A, Isa SI, Nakahama K,
Okishio K, Shiroyama T, Suzuki H, Inoue T, Tamiya M, Hirashima T,
et al: Predictive factors for poor progression-free survival in
patients with non-small cell lung cancer treated with nivolumab.
Anticancer Res. 37:5857–5862. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Oya Y, Yoshida T, Kuroda H, Mikubo M,
Kondo C, Shimizu J, Horio Y, Sakao Y, Hida T and Yatabe Y:
Predictive clinical parameters for the response of nivolumab in
pretreated advanced non-small-cell lung cancer. Oncotarget.
8:103117–103128. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Mezquita L, Auclin E, Ferrara R, Charrier
M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L,
Audigier-Valette C, et al: Association of the lung immune
prognostic index with immune checkpoint inhibitor outcomes in
patients with advanced non-small cell lung cancer. JAMA Oncol.
4:351–357. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bagley SJ, Kothari S, Aggarwal C, Bauml
JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson
JC, et al: Pretreatment neutrophil-to-lymphocyte ratio as a marker
of outcomes in nivolumab-treated patients with advanced
non-small-cell lung cancer. Lung Cancer. 106:1–7. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Mantovani A, Schioppa T, Porta C, Allavena
P and Sica A: Role of tumor-associated macrophages in tumor
progression and invasion. Cancer Metastasis Rev. 25:315–322.
2006.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Mantovani A, Marchesi F, Malesci A, Laghi
L and Allavena P: Tumour-associated macrophages as treatment
targets in oncology. Nat Rev Clin Oncol. 14:399–416.
2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Yuan A, Hsiao YJ, Chen HY, Chen HW, Ho CC,
Chen YY, Liu YC, Hong TH, Yu SL, Chen JJ and Yang PC: Opposite
effects of M1 and M2 macrophage subtypes on lung cancer
progression. Sci Rep. 5(14273)2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Myers KV, Pienta KJ and Amend SR: Cancer
cells and M2 macrophages: Cooperative invasive ecosystem engineers.
Cancer Control. 27(1073274820911058)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Obeid M, Panaretakis T, Tesniere A, Joza
N, Tufi R, Apetoh L, Ghiringhelli F, Zitvogel L and Kroemer G:
Leveraging the immune system during chemotherapy: Moving
calreticulin to the cell surface converts apoptotic death from
‘silent’ to immunogenic. Cancer Res. 67:7941–7944. 2007.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Chen N, Fang W, Zhan J, Hong S, Tang Y,
Kang S, Zhang Y, He X, Zhou T, Qin T, et al: Upregulation of PD-L1
by EGFR activation mediates the immune escape in EGFR-driven NSCLC:
Implication for optional immune targeted therapy for NSCLC patients
with EGFR Mutation. J Thorac Oncol. 10:910–923. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Mandai M, Hamanishi J, Abiko K, Matsumura
N, Baba T and Konishi I: Dual faces of IFNγ in cancer progression:
A role of PD-L1 induction in the determination of pro- and
antitumor immunity. Clin Cancer Res. 22:2329–2334. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Sugiyama E, Togashi Y, Takeuchi Y, Shinya
S, Tada Y, Kataoka K, Tane K, Sato E, Ishii G, Goto K, et al:
Blockade of EGFR improves responsiveness to PD-1 blockade in
EGFR-mutated non-small cell lung cancer. Sci Immunol.
5(eaav3937)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Templeton AJ, McNamara MG, Seruga B,
Vera-Badillo FE, Aneja P, Ocana A, Leibowitz-Amit R, Sonpavde G,
Knox JJ, Tran B, et al: Prognostic role of neutrophil-to-lymphocyte
ratio in solid tumors: A systematic review and meta-analysis. J
Natl Cancer Inst. 106(dju124)2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Jin J, Yang L, Liu D and Li W: Association
of the neutrophil to lymphocyte ratio and clinical outcomes in
patients with lung cancer receiving immunotherapy: A meta-analysis.
BMJ Open. 10(e035031)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Gooden MJ, de Bock GH, Leffers N, Daemen T
and Nijman HW: The prognostic influence of tumour-infiltrating
lymphocytes in cancer: A systematic review with meta-analysis. Br J
Cancer. 105:93–103. 2011.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hiramatsu S, Tanaka H, Nishimura J,
Sakimura C, Tamura T, Toyokawa T, Muguruma K, Yashiro M, Hirakawa K
and Ohira M: Neutrophils in primary gastric tumors are correlated
with neutrophil infiltration in tumor-draining lymph nodes and the
systemic inflammatory response. BMC Immunol. 19(13)2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Petrie HT, Klassen LW and Kay HD:
Inhibition of human cytotoxic T lymphocyte activity in vitro by
autologous peripheral blood granulocytes. J Immunol. 134:230–234.
1985.PubMed/NCBI
|
|
30
|
Theelen W, Peulen HMU, Lalezari F, van der
Noort V, de Vries JF, Aerts J, Dumoulin DW, Bahce I, Niemeijer AN,
de Langen AJ, et al: Effect of pembrolizumab after stereotactic
body radiotherapy vs pembrolizumab alone on tumor response in
patients with advanced non-small cell lung cancer: Results of the
PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol.
5:1276–1282. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Shaverdian N, Lisberg AE, Bornazyan K,
Veruttipong D, Goldman JW, Formenti SC, Garon EB and Lee P:
Previous radiotherapy and the clinical activity and toxicity of
pembrolizumab in the treatment of non-small-cell lung cancer: A
secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol.
18:895–903. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Li L, Lu G, Liu Y, Gong L, Zheng X, Zheng
H, Gu W and Yang L: Low infiltration of CD8+ PD-L1+ T cells and M2
macrophages predicts improved clinical outcomes after immune
checkpoint inhibitor therapy in non-small cell lung carcinoma.
Front Oncol. 11(658690)2021.PubMed/NCBI View Article : Google Scholar
|
